Lazard Asset Management
HRMY icon

Lazard Asset Management’s Harmony Biosciences HRMY Stock Holding History

Lazard Asset Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1M Sell
27,600
-6,206
-18% -$196K ﹤0.01% 1228
2026
Q1 		$947K Buy
33,806
+2,703
+9% +$88.6K ﹤0.01% 1193
2025
Q4 		$1.16M Sell
31,103
-2,588
-8% -$85.1K ﹤0.01% 1108
2025
Q3 		$929K Sell
33,691
-45,052
-57% -$1.55M ﹤0.01% 1165
2025
Q2 		$2.49M Sell
78,743
-36,110
-31% -$1.16M ﹤0.01% 939
2025
Q1 		$3.81M Buy
114,853
+105,629
+1,145% +$3.79M 0.01% 762
2024
Q4 		$316K Buy
9,224
+2,541
+38% +$87.3K ﹤0.01% 1492
2024
Q3 		$266K Sell
6,683
-6
-0.1% -$211 ﹤0.01% 1541
2024
Q2 		$200K Buy
6,689
+2,147
+47% +$64.6K ﹤0.01% 1558
2024
Q1 		$152K Buy
4,542
+2,251
+98% +$72.3K ﹤0.01% 1397
2023
Q4 		$73K Buy
2,291
+109
+5% +$3.04K ﹤0.01% 1784
2023
Q3 		$71K Buy
2,182
+427
+24% +$14.8K ﹤0.01% 1751
2023
Q2 		$61K Buy
+1,755
New +$60.6K ﹤0.01% 1765
2022
Q3 		– Sell
-1,566
Closed -$76K – 2425
2022
Q2 		$76K Buy
+1,566
New +$70.5K ﹤0.01% 1619

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lazard Asset Management's HRMY Position: Q2 2026 in Review

Lazard Asset Management reduced its Harmony Biosciences (HRMY) stake by 18% in Q2 2026, selling an estimated $196K and leaving 27,600 shares worth $1M. The position accounts for ﹤0.01% of the portfolio, ranked #1228.

Lazard Asset Management first reported a position in HRMY in Q2 2022 and has held it in 14 quarters since. The position peaked at $3.81M in Q1 2025. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Lazard Asset Management held 27,600 shares of Harmony Biosciences worth $1M as of Q2 2026.
  • Lazard Asset Management sold 6,206 Harmony Biosciences shares in Q2 2026, an estimated $196K.
  • Harmony Biosciences made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1228 holding.
  • Lazard Asset Management first reported a position in Harmony Biosciences in Q2 2022 and has held it in 14 quarters since.
  • Lazard Asset Management's Harmony Biosciences position peaked at $3.81M in Q1 2025.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.